Becton
Dickinson Introduces the VACUTAINER® Brand ECLIPSE™ Blood Collection
Needle
A New Safety-Engineered Product Requires No
Change of Technique.
Compatible with All VACUTAINER System Products.
|
|
|
|
Contact: Camilla B. Jenkins BD (201)
847-5369
|
Franklin
Lakes, NJ -- Tuesday, February 02, 1999 -- BD [Nyse: BDX]
today announced the introduction in the United States of the new
VACUTAINER® Brand ECLIPSE blood collection needle with a unique,
fully-integrated shielding device to help protect health care
workers from accidental injury.
Our goal at BD is to deliver the highest quality patient care,
while also protecting the doctors, nurses and technicians who use
our products to care for others every day, said Richard Brajer,
President, Sample Collection Worldwide at BD. The ECLIPSE blood
collection needle not only delivers advanced protection technology
for health care workers, it includes the proven quality and
performance of the VACUTAINER Brand PRECISIONGLIDE needle and is
compatible with all the products in the VACUTAINER Brand sample
collection system.
The ECLIPSE safety shield is attached directly to a standard
blood collection needle and already aligned with the bevel of the
needle, so no extra assembly or adjustment is required by the user.
The intuitive design of the advanced protection technology means
there is no need to change the standard, one-handed venipuncture
technique when using the ECLIPSE needle. The procedure remains
familiar and the users other hand is free to apply pressure to the
patients puncture site. The ECLIPSE shield is activated immediately
after the needle is removed from the vein. When the thumb pushes
forward on the shield, an audible click indicates that the safety
shield is locked in place. The ECLIPSE shield has minimal impact on
waste disposal.
|
This press release
may contain certain forward-looking statements (as defined under
Federal securities laws) regarding the company's performance,
including future revenues, products and income, which are based upon
current expectations of the company and involve a number of business
risks and uncertainties. Actual results could vary materially from
anticipated results described in any forward- looking statement.
Factors that could cause actual results to vary materially include,
but are not limited to, competitive factors, changes in regional,
national or foreign economic conditions, changes in interest or
foreign currency exchange rates, delays in product introductions,
year 2000 issues, and changes in health care or other governmental
regulation, as well as other factors discussed herein and in the
company's filings with the Securities and Exchange
Commission. |
|
|
 |
 | |